Over the past decade an increasing interest in the use of biomarkers that are disease-specific to improve the diagnostic, prognostic, and therapeutic approach of different human pathologies has been observed.
Biomarkers have to be measurable in body fluids and able to address unmet clinical needs for the detection of a tissue injury. In particular, biochemical markers of brain damage, both in adult and in paediatric population, have been object of growing interest.
From the 90s onwards, deep evidence about brain plasticity throughout a person's lifespan has been accumulated, in contrast to the previous belief of a nonmutable system. Brain, in effect, is a complex network of different cell subsets that can not only be rewired, but it can also be structurally remodeled. The main consequence of neuroplasticity is the ability of several stimuli, from normal daily experience to damage, or recovery, to modulate the brain activity. The brain compensates for damage by reorganizing and forming new connections between intact neurons. Following a brain injury, in fact, a destructive cascade of biological events continues over hours and days that may worsen the patient's condition. Research studies on markers of brain damage both in humans and in specific animal model might help to understand the underlying mechanisms disrupting this plasticity and giving new insight into several human disease states.
In the current special issue, this topic has been addressed in both experimental and clinical studies, in Last but not least, this special issue also focuses on the need of trustable biomarkers for early diagnosis of brain damage when insult has already occurred and clinical 
